Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
INCLUSION CRITERIA:~* 2 - 18 years of age~* SOJRA for at least 3 months, with stable systemic features~* If taking methotrexate, hydroxychloroquine, or NSAIDs, dose must be stable~* Must take prednisone at a stable dose~EXCLUSION CRITERIA:~* Need for other DMARDs or prestudy requirements for oral or parenteral pulse steroids or intra-articular steroids~* Pregnant or nursing female~* Clinically significant abnormal laboratory test results for blood cells, liver or kidney function, or serology~* Previous receipt of any tumor necrosis factor (TNF) inhibitor~* Live virus vaccine within 12 weeks of study entry~* Participation in another study requiring informed consent within 12 weeks of entry~* Diabetes that requires insulin treatment~* Infection, chronic, recurrent, or currently active~* Any serious medical or psychiatric condition or history of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Etanercept (Type: EXPERIMENTAL): Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months.
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
- Part 2: Etanercept (Type: EXPERIMENTAL): Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
- Part 3: (Type: EXPERIMENTAL): Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).